肿瘤坏死因子受体选择性拮抗剂的研究进展

江海龙; 王宁远; 陆一鸣

doi:10.3969/j.issn.1006-0111.2015.05.003

肿瘤坏死因子受体选择性拮抗剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.05.003

1.
第二军医大学药学院微生物与生化药学教研室, 上海 200433
2.
第二军医大学药学院微生物与生化药学教研室, 上海 200433;福建中医药大学药学院, 福建福州 350108

基金项目: 国家自然科学基金(30500093);国家科技部"重大新药创制"专项(2009ZX09103-690);上海市科委重点项目(04JC14002);军队"十一五"计划(06Q042);上海市高校优秀青年教师科研专项基金(ejd09011)

Research advance of selective inhibitor of tumornecrosis factor receptor

1.
Department of Microbial and Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
2.
Department of Microbial and Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China;FuJian University of Traditional Chinese Medicine, Fuzhou 350108, China

摘要: 肿瘤坏死因子(TNF)信号通路是很有价值的治疗靶标,抗TNF药物已成功治疗自身免疫和炎症疾病,但传统的抗TNF药物完全封闭TNF信号通路,导致影响自身的免疫调节和监视功能而增加感染、致癌的风险和产生新的自身免疫疾病。选择性抑制sTNF/TNFR1而保留mTNF/TNFR2传导的信号能减少副作用而不降低治疗效果。该文探讨了选择性抑制TNFR1介导的信号通路对治疗TNF相关疾病的意义,分析TNF识别并激活肿瘤坏死因子受体(TNFR)的作用机制,可能会为设计新药提供新的思路。
- 肿瘤坏死因子受体 /
- 选择性拮抗 /
- 药物靶点
Abstract: TNF signaling pathway was a valuable target, and anti-TNF drugs were successfully used to treat autoimmune and inflammatory diseases.But this therapy abrogate some beneficial TNF signaling, leading to increased risk of infection and malignancy, and the onset of new auto-immune diseases. Inhibiting the soluble TNF/TNFR1 axis while saving the beneficial transmembrane TNF/TNFR2 signaling untouched was a new approach.Because it inhibited the pathological effects of TNF and reduced the side effects, and opened the way for the treatment of other diseases in which TNFR2 inhibition was detrimental.The significance of the selective inhibition of TNFR1-mediated signaling pathways for TNF-related diseases was discussed and the mechanism of TNF identification TNFR was clarified, which might provide new ideas for the design of new drugs.
- TNFR /
- selective inhibition /
- drug target

[1]	Apostolaki M, Armaka M, Victoratos P,et al.Cellular mechanisms of TNF function in models of inflammation and autoimmunity[J].Curr Dir Autoimmun, 2010,11(2):1-26.
[2]	Mukai Y,Nakamura T, Yoshikawa M,et al. Solution of the structure of the TNF-TNFR2 complex[J]. Sci Signal,2010,3 (148): 1-10.
[3]	Hehlgans T, Pfeffer K. The intriguing biology of the tumounecrosis factor/tumour necrosis factor receptor superfamily players,rules and the games[J].Immunology,2005,115(1):1-20.
[4]	Mcllwain DR,Lang PA,Maretzky T,et al.IRhom2 regulation of TACE controls TNF-mediated protection against listeria and responses to LPS[J].Science,2012,335(6065):229-232.
[5]	Chen X, Wu X, Zhou Q,et al.TNFR2 is critical for the stabilization of the CD4+Foxp3+ Regulatory T cell phenotype in the inflammatory environmentl[J]. J Immuno,2013, 190(3):1076-1084.
[6]	Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases[J].Nat Rev Drug Discov, 2010, 9(6):482-493.
[7]	Magis C, van der Sloot AM, Serrano L,et al. An improved understanding of TNFL/TNFR interactions using structure-based classi cations[J].Trends Biochem Sci,2012,37(9):353-363.
[8]	Dixon,Hyrich KL, Watson KD,et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)[J]. Ann Rheum Dis,2010,69(3):522-528.
[9]	Takeuchi T, Tatsuki Y, NogamiY,et al. Post marketing surveillance of the safety profile of infliximab in 5 000 Japanese patients with rheumatoid arthritis[J].Ann Rheum Dis,2008, 67(2):189-194.
[10]	Tang W, Lu Y, Tian QY,et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice[J]. Science, 2011, 332(6028): 478-484.
[11]	Deng GM, Zheng LX,Lenardo M,et al. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors[J].Nat Med,2005,10(11):1066-1072.
[12]	Hwang JR, Huh JH, Lee Y,et al. Insulin-like growth factor-binding protein-5 (IGFBP-5) inhibits TNF-a-induced NF-κB activity by binding to TNFR1[J]. Biochem Biophys Res Commun, 2011,405(4): 545-551.
[13]	Mukai Y, Shibata H, Nakamura T,et al. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant[J].J Mol Biol, 2009, 385(4):1221-1229.
[14]	Takasaki W,KajinoY,KajinoK,et al.Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF-αbinding to its receptor[J]. Nat Biotechnol, 1997, 15:1266-1270.
[15]	Mukaro. Selective activation of tumour necrosis factor receptor-mediated intacellular signalling pathways[D].Adelaide: School of Paediatrics and Reproductive Health,2009.
[16]	Chidnos-Rojas CL,Steward MW,PartidosCD,et al.Apeptidomimetic antagonist of TNF-alpha-mediated cytotoxicity identified from a phage-displayed random peptide library[J]. J Immunol,1998,161(10):5621-5626.
[17]	尹丙姣,黄丽霞,梁慧芳,等.TNFR1封闭肽-hIgGFc融合蛋白和TNFR1封闭肽对TNF-α介导的生物学效应的封闭作用[J].中国免疫学杂志,2008,24(9):776-780.
[18]	Liang H, Yin B, Zhang H,et al. Blockade of tumor necrosis factor (TNF) receptor type1-mediated TNF-α signaling protected wistarrats from diet-Induced obesity and insulin resistance[J]. Endocrinology, 2008, 149(6):2943-2951.
[19]	Roland E,Sabine M,Jens N,et al. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF)action[J].J Immunother,2008,31(3):225-234.
[20]	Carter PH, Scherle PA, Muckelbauer JK,et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-a[J]. PNAS, 2001,98(21):11879-11884.
[21]	Murali R, Cheng X, Berezov A,et al. Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107[J]. PNAS,2005,102(31):10970-10975.

[1]	杨嘉宁, 赵一颖, 肖伟. 七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
[2]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[3]	戴菲菲, 傅翔, 陈琼年, 俞苏纯. 上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
[4]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[5]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[6]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[7]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[8]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[9]	毛智毅, 王筱燕, 陈晓颖, 汤逸斐. 度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
[10]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[11]	夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞. 核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
[12]	陈怡君, 王卓, 何苗, 张宇, 田泾. 泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
[13]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
[14]	张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫. 基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
[15]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[16]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062

点击查看大图

计量

文章访问数: 3778
HTML全文浏览量: 356
PDF下载量: 685
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

肿瘤坏死因子受体选择性拮抗剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.05.003

Research advance of selective inhibitor of tumornecrosis factor receptor

计量

肿瘤坏死因子受体选择性拮抗剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.05.003

1. 第二军医大学药学院微生物与生化药学教研室, 上海 200433

2. 第二军医大学药学院微生物与生化药学教研室, 上海 200433;福建中医药大学药学院, 福建福州 350108

English Abstract

Research advance of selective inhibitor of tumornecrosis factor receptor

全文HTML

目录

留言板

肿瘤坏死因子受体选择性拮抗剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.05.003

Research advance of selective inhibitor of tumornecrosis factor receptor

计量

出版历程

肿瘤坏死因子受体选择性拮抗剂的研究进展

doi: 10.3969/j.issn.1006-0111.2015.05.003

1. 第二军医大学药学院微生物与生化药学教研室, 上海 200433 2. 第二军医大学药学院微生物与生化药学教研室, 上海 200433;福建中医药大学药学院, 福建 福州 350108

English Abstract

Research advance of selective inhibitor of tumornecrosis factor receptor

全文HTML

目录

1. 第二军医大学药学院微生物与生化药学教研室, 上海 200433

2. 第二军医大学药学院微生物与生化药学教研室, 上海 200433;福建中医药大学药学院, 福建福州 350108